Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067) Meeting Abstract
| Authors: | Wolchok, J. D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Ferrucci, P. F.; Smylie, M.; Dummer, R.; Hill, A. G.; Haanen, Jbag; Maio, M.; McArthur, G. A.; Yang, A.; Rollin, L.; Horak, C. E.; Larkin, J. M. G.; Hodi, F. S. |
| Abstract Title: | Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904630 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.lba1 |
| Notes: | Meeting Abstract: LBA1 -- Source: Wos |
